research use only

Equol Estrogen/progestogen Receptor agonist

Name: Equol
Brand: Selleck Chemicals
SKU: S2450
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S2450

Equol, a metabolite of soybeans, is an important isoflavone in humans, specifically binds to 5α-DHT, and has a modest affinity for recombinant estrogen receptor ERβ. Phase 2.

Chemical Structure

Molecular Weight: 242.27

Jump to

Quality Control

Batch: Purity: 99.07%

99.07

Related Targets	Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR
Other Estrogen/progestogen Receptor Inhibitors	Elacestrant (RAD1901) Dihydrochloride MPP dihydrochloride Cholesterol Endoxifen HCl G15 Chrysin Licochalcone A AZD9496 PHTPP Liquiritigenin

Solubility

In vitro
Batch:

DMSO : 48 mg/mL (198.12 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 48 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	242.27	Formula	C₁₅H₁₄O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	531-95-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1C(COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O

Mechanism of Action

Features	A chiral molecule that can exist as the enantiomers R-equol and S-equol.
Targets/IC₅₀/Ki	ERβ
In vitro	Equol is a metabolite produced from the soy phytoestrogen daidzein by the action of gut microflora. This compound has higher affinity for both ERs (estrogen receptors including ERalpha and ERbeta). It exists as the enantiomers R-equol and S-equol. S-equol has a high binding affinity, preferential for ERbeta with a K_i of 16 nM whereas R-equol binds more weakly and with a preference for ERalpha K with a K_i of 50 nM. This metabolite is superior to all other isoflavones in its antioxidant activity. It has antioestrogenic properties. This compound is a 100-fold more potent than daidzein in stimulating an oestrogenic response. It is also more effective than daidzein in competing with ³ H-oestradiol for binding to the ER. This chemical stimulates the growth of MCF-7 cells in a concentration-dependent manner. Although it exhibits oestrogenic activity, exposure of MCF-7 cells to this compound simultaneously with oestradiol is effective in reducing pS2 mRNA expression. It results in the downregulation of ER mRNA expression.
References	[1] https://pubmed.ncbi.nlm.nih.gov/15018930/ [2] https://pubmed.ncbi.nlm.nih.gov/12468591/ [3] https://pubmed.ncbi.nlm.nih.gov/6128595/ [4] https://pubmed.ncbi.nlm.nih.gov/9616286/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06133101	Recruiting	Non-Alcoholic Fatty Liver Disease	Marialena Mouzaki\|Children''s Hospital Medical Center Cincinnati	January 15 2024	Phase 2
NCT06398236	Recruiting	Menopause	Nutrition & Sante Iberia\|Adknoma Health Research	March 17 2023	Not Applicable
NCT01982578	Completed	Alzheimer''s Disease	Fundación para la Investigación del Hospital Clínico de Valencia\|University of Valencia	September 1 2017	Not Applicable
NCT03101085	Completed	Alzheimer Disease	Russell Swerdlow\|Ausio Pharmaceuticals LLC\|University of Kansas Medical Center	May 5 2017	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):